Certara (CERT) drew investor attention after announcing a partnership with NVIDIA to integrate the BioNeMo Agent Toolkit into its open AI platform for biosimulation and regulatory workflows in drug development.

At a share price of $6.79, Certara has seen a 30-day share price return of 30.58%, although the year to date share price return is down 22.31% and the 1-year total shareholder return is down 39.05%. This suggests that recent momentum follows a much weaker longer term record.

If this AI-driven update has your attention, it may be worth broadening your watchlist with other healthcare focused AI stocks through the Simply Wall St screener, starting with 40 healthcare AI stocks.

Bulls will argue Certara’s NVIDIA tie up and improving net income growth justify the recent share price rebound, while bears point to the multi year shareholder losses and current loss making status. What story do the valuation numbers tell next?

Most Popular Narrative: 9.2% Undervalued

Against Certara’s last close of $6.79, the most followed narrative implies a fair value of $7.48. This points to modest upside that hinges on how its biosimulation and model informed drug development strategy plays out.

The upcoming commercial launch of Certara's next-generation, AI-enabled MIDD platform and CertaraIQ QSP software leverages advanced analytics and machine learning, providing differentiated capabilities that democratize access and increase the potential customer base, which should translate to higher recurring revenue and margin expansion through cloud-based SaaS models.

Want to see what sits behind that valuation gap? The narrative focuses on measured revenue expansion, a shift toward higher margin software and a future earnings profile that assumes investors accept a rich multiple. Curious which specific growth and profitability targets need to line up to support that price tag?

Result: Fair Value of $7.48 (UNDERVALUED)

However, Certara’s story could change quickly if large pharma customers slow biosimulation adoption, or if rising R&D and AI investment fails to produce the expected payoff.

Another View: What Certara’s Sales Multiple Is Telling You

The SWS DCF model points to Certara being 50.7% below an estimated fair value of $13.78, yet the market is pricing the stock at a P/S of 2.5x, which is higher than both the US Healthcare Services industry at 2.5x and the peer average at 2.3x, and above a fair ratio of 1.5x. That mix of discount on one model and premium on another raises a simple question: which signal do you trust more for your own hurdle rate?

Next Steps

If the mixed sentiment around Certara has you on the fence, move quickly from reading to checking the data for yourself and shaping your own thesis with 2 key rewards.

Looking for more investment ideas beyond Certara?

If Certara has sharpened your focus, do not stop at one stock. Use targeted screens to quickly surface other opportunities that match how you like to invest.

• Target potential mispricing by reviewing companies highlighted in the 46 high quality undervalued stocks and see which ones line up with your return and risk expectations.
• Prioritize resilience by scanning the 80 resilient stocks with low risk scores so you can focus on stocks that align with a steadier risk profile.
• Spot early stage opportunities with quality traits using the screener containing 20 high quality undiscovered gems before they sit firmly on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.